FDA Clears Pfizer's Xeljanz for Inflammatory Bowel Disease

(Reuters)—The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc’s drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis.

The effectiveness of Xeljanz (tofacitinib) in treating ulcerative colitis was shown in three controlled clinical trials, including two trials that showed the drug caused disease remission in about 17-18 percent of the patients.

The FDA’s announcement is here: http://bit.ly/2kA4FJN.

The drug is already approved by the FDA to treat rheumatoid arthritis and psoriatic arthritis.

(Reuters)—U.S. health regulators declined to approve Pfizer Inc’s oral rheumatoid arthritis drug Xeljanz (tofacitinib) to treat moderate to severe cases of plaque psoriasis, the drugmaker said on Wednesday. Pfizer said it received a complete response letter from the Food and Drug Administration. Such letters typically outline concerns and conditions that must be addressed in order…

(Reuters Health)—Doctors know smoking can increase the risk for certain common inflammatory bowel diseases (IBD), but many patients haven’t gotten the message, a new study suggests. Out of 239 patients with two common types of IBD (Crohn’s disease and ulcerative colitis) only half were aware of the smoking risks associated with these conditions. ad goes…

NEW YORK (Reuters Health)—Dose optimization of infliximab is needed much earlier in ulcerative colitis than in Crohn’s disease, a single-center retrospective study reveals. “We compared the rates of dose increases over a fairly lengthy period of time,” said Dr. Mark Silverberg, the study’s senior author from the Mount Sinai Hospital in Toronto. ad goes here:advert-1ADVERTISEMENTSCROLL…

Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.

FDA Clears Pfizer’s Xeljanz for Inflammatory Bowel Disease

FDA Declines to Expand Approval of Pfizer Arthritis Drug Xeljanz

Patients Don’t Realize Smoking Worsens Inflammatory Bowel Disease

Studies Challenge Conventional Infliximab Protocols in IBD

Gut Feeling: A Comprehensive Look at the Pathogenesis, Management & Treatment of Inflammatory Bowel Disease

Related Articles